Monday, March 2, 2015

Lyric Pharmaceuticals Gets $20.4M For GI Disease Research

South San Francisco-based Lyric Pharmaceuticals, a company developing therapeutics for gastrointestinal diseases, said last week that it has raised $20.4M in a Series A financing round. The funding was led by Rivervest Venture Partners, Sante Ventures, and Third Point Ventures, and also included Aperture Venture Partners. The firm's founders are David Wurtman and M. Scott Harris.